度洛西汀治疗早期乳腺癌芳香化酶抑制剂相关关节痛的随机对照试验:SWOG S1202
SWOG S1202是一项随机、双盲、多中心、安慰剂对照的III期试验,纳入299例接受芳香化酶抑制剂治疗且平均关节痛评分≥4分的早期乳腺癌绝经后女性,随机接受度洛西汀或安慰剂治疗13周。结果显示,12周时度洛西汀组平均关节痛评分较安慰剂组降低0.82分(95%CI -1.24至-0.40;
要点
- 度洛西汀可显著改善AI相关关节痛,12周平均疼痛评分降低0.82分。
- 度洛西汀组任何级别不良事件更常见(78% vs 50%),3级事件无差异。
- 该研究支持度洛西汀用于改善早期乳腺癌患者AIMSS症状。
核心结论
- 在早期乳腺癌接受AI治疗的患者中,度洛西汀改善AIMSS优于安慰剂,但低级别毒性更常见。
研究设计与样本
- 随机、双盲、多中心、安慰剂对照III期试验,纳入299例AI治疗的早期乳腺癌绝经后女性,随机1:1接受度洛西汀或安慰剂13周。
主要发现
- 最严重关节痛、关节僵硬、疼痛干扰和功能方面观察到类似改善趋势。
- 度洛西汀组任何级别不良事件发生率为78%,安慰剂组为50%;3级不良事件发生率相似。
关键数值与推荐
- 主要终点为12周内平均关节痛评分,采用多变量线性混合模型调整分层因素(基线疼痛评分4-6 vs 7-10和既往紫杉烷使用)。
- 临床显著疼痛改善定义为平均疼痛评分较基线下降≥2分。
临床怎么用
- 对于AI相关关节痛且平均疼痛评分≥4分的早期乳腺癌绝经后患者,可考虑使用度洛西汀改善症状。
- 使用度洛西汀时需注意低级别不良事件的发生率较高。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Purpose Adherence to aromatase inhibitor (AI) therapy for early-stage breast cancer is limited by AI-associated musculoskeletal symptoms (AIMSS). Duloxetine is US Food and Drug Administration approved for treatment of multiple chronic pain disorders. We hypothesized that treatment of AIMSS with duloxetine would improve average joint pain compared with placebo. Methods This randomized, double-blind, phase III trial included AI-treated postmenopausal women with early-stage breast cancer and who had average joint pain score of ≥ 4 out of 10 that developed or worsened since AI therapy initiation. Patients were randomly assigned 1:1 to duloxetine or placebo for 13 weeks. The primary end point was average joint pain through 12 weeks, examined using multivariable linear mixed models, adjusted for stratification factors (baseline pain score of 4 to 6 v 7 to 10 and prior taxane use). Clinically significant change in average pain was defined as a ≥ 2-point decrease from baseline. Results Of 299 enrolled patients, 127 patients treated with duloxetine and 128 who received placebo were evaluable for the primary analysis. By 12 weeks, the average joint pain score was 0.82 points lower for patients who received duloxetine compared with those who received placebo (95% CI, -1.24 to -0.40; P = .0002). Similar patterns were observed for worst joint pain, joint stiffness, pain interference, and functioning. Rates of adverse events of any grade were higher in the duloxetine-treated group (78% v 50%); rates of grade 3 adverse events were similar. Conclusion Results of treatment with duloxetine for AIMSS were superior to those of placebo among women with early-stage breast cancer, although it resulted in more frequent low-grade toxicities.
引用
- Henry NL, Unger JM, Schott AF, et al. Randomized, Multicenter, Placebo-Controlled Clinical Trial of Duloxetine Versus Placebo for Aromatase Inhibitor-Associated Arthralgias in Early-Stage Breast Cancer: SWOG S1202. J Clin Oncol. 2017. PMID: 29136387. doi:10.1200/JCO.2017.74.6651
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。